IntelGenx Technologies Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Tommy Kenny
- Full Time Employees
- 48
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 6420 Abrams Montreal QC Canada H4S 1Y2
- IPO Date
- Jan 17, 2007
- CIK
- 0001098880
- Website
- intelgenx.com
- Similar Companies
- Business
- IntelGenx Technologies Corp. (IGXT), now operating as Nualtis, develops and manufactures innovative oral thin film drug delivery products for the pharmaceutical, human health, and animal health markets. The company leverages proprietary platforms including VersaFilm for human health applications such as migraine treatments like Rizatriptan (INT0008/2008), erectile dysfunction therapies (INT0007/2006), opioid addiction management (INT0027/2011), schizophrenia and bipolar disorder films (INT0036/2013), neuropathic pain and nausea relief (INT0010/2006), and montelukast films for Alzheimer’s and Parkinson’s (INT0043/2015); VetaFilm for veterinary stress-free dosing with palatable, room-stable films; and VevaDerm for additional delivery innovations, alongside full-service offerings in R&D partnerships, GMP manufacturing, analytical method development, regulatory support, and clinical monitoring. It also advances pipeline candidates like INT0039/2013 for pain, INT0053/2020 and VLS-01 for resistant depression, and INT0048/2020 for animal health, with geographic operations centered in Canada and targeting global partners.[image from website] Founded in 2003 and headquartered at 6420 Abrams, Ville Saint-Laurent, Quebec, Canada, IntelGenx provides comprehensive pharmaceutical services including formulation optimization, stability studies, IP strategy, and scale-up production inspected by FDA and Health Canada. In recent major developments, atai Life Sciences AG completed its acquisition of IntelGenx in October 2024 via a credit bid discharging senior secured debt for equity, integrating VLS-01 into atai's portfolio with Phase 2 trials planned by year-end; this followed CCAA protection in mid-2024, a court-approved sale and investment solicitation process with atai as stalking horse bidder, and multiple loan amendments including a third restated agreement in March 2024 providing up to $2 million in convertible financing.
IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG
IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process
IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA' Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease
IntelGenx Announces Initiation of the Sale and Investment Solicitation Process
IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process
IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives
IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives
IntelGenx Announces Voting Results on Election of Directors
IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK' Clinical Trial
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
IntelGenx Technologies Corp. (IGXT) Q4 2023 Earnings Call Transcript
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering
IntelGenx Launches Preferred Share Regulation A Offering
IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®
IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000
IntelGenx Announces Shareholder Approval of Financing Transactions
IntelGenx Receives Approval to Conduct 'MONTPARK' Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease